EHA Library - The official digital education library of European Hematology Association (EHA)

PERIOSTITIS - A RARE COMPLICATION OF VORICONAZOLE
Author(s): ,
Santanu Sen
Affiliations:
Dept of Paediatric Oncology & BMT,Kokilaben Dhirubhai Ambani Hospital,Mumbai,India
,
Sameer Tulpule
Affiliations:
Dept of Oncology & BMT,Kokilaben Dhirubhai Ambani Hospital,Mumbai,India
,
Sruthi Sivadasan
Affiliations:
Dept of Paediatric Oncology & BMT,Kokilaben Dhirubhai Ambani Hospital,Mumbai,India
,
Tanu Singhal
Affiliations:
Dept of Paediatric Oncology & BMT,Kokilaben Dhirubhai Ambani Hospital,Mumbai,India
Khushnuma Mullanfiroze
Affiliations:
Dept of Paediatric Oncology & BMT,Kokilaben Dhirubhai Ambani Hospital,Mumbai,India
(Abstract release date: 05/17/18) EHA Library. Sen S. 06/14/18; 216785; PB2064
Santanu Sen
Santanu Sen
Contributions
Abstract

Abstract: PB2064

Type: Publication Only

Background
Voriconazole is commonly used antifungal agent used in paediatric oncology patients for prophylaxis and treatment of fungal infections. We report here on one of our post transplant patients who presented with acute bone pain over the tibia.

Aims
To describe a uncommon complication of Voriconaole use that can be confused with relapse of disease.

Methods
A 6 year old boy with relapsed B cell ALL had a successful matched sibling donor transplant. Post transplant, patient was given presumptive therapy with liposomal amphotericin as his galactomannan screen was positive. Later his antifungal therapy was switched to voriconazole  and he was discharged on the same.

Voriconazole levels were monitored and kept at a therapeutic level. On Day + 45 patient presented with severe  leg pain and difficulty in walking. There were no neurological findings and a X Ray of the legs were normal. Suspecting a relapse, a bone marrow aspiration and biopsy was done which showed no evidence of disease recurrence with MRD being negative and 100% donor chimerism.

The pain increased in severity to an extent that the child stopped walking. A MRI scan was done which only showed periosteal thickening suggestive of mild periostitis over the tibia. Differential diagnosis of leukemic infiltration, osteomyelitis and drug induced periostitis was considered. As we had ruled out a relapse with a bone marrow examination and all inflammatory markers were negative, we deduced that drug induced periostitis was the most likely cause for the symptoms. Discontinuation of voriconazole led to complete resolution of pain within 48 hours.

Results
At one year post transplant, patient continued to be in remission and pain free.

Conclusion
Painful periostitis is a rare complication of long term voriconazole therapy which has only been recently reported in literature. Fluorosis and promotion of bone formation by osteoblast stimulation is the the proposed mechanism for voriconazole induced periostitis. Increased awareness of this rare condition can lead early correct diagnosis.

Session topic: 31. Infectious diseases, supportive care

Keyword(s): Side effects, Voriconazole

Abstract: PB2064

Type: Publication Only

Background
Voriconazole is commonly used antifungal agent used in paediatric oncology patients for prophylaxis and treatment of fungal infections. We report here on one of our post transplant patients who presented with acute bone pain over the tibia.

Aims
To describe a uncommon complication of Voriconaole use that can be confused with relapse of disease.

Methods
A 6 year old boy with relapsed B cell ALL had a successful matched sibling donor transplant. Post transplant, patient was given presumptive therapy with liposomal amphotericin as his galactomannan screen was positive. Later his antifungal therapy was switched to voriconazole  and he was discharged on the same.

Voriconazole levels were monitored and kept at a therapeutic level. On Day + 45 patient presented with severe  leg pain and difficulty in walking. There were no neurological findings and a X Ray of the legs were normal. Suspecting a relapse, a bone marrow aspiration and biopsy was done which showed no evidence of disease recurrence with MRD being negative and 100% donor chimerism.

The pain increased in severity to an extent that the child stopped walking. A MRI scan was done which only showed periosteal thickening suggestive of mild periostitis over the tibia. Differential diagnosis of leukemic infiltration, osteomyelitis and drug induced periostitis was considered. As we had ruled out a relapse with a bone marrow examination and all inflammatory markers were negative, we deduced that drug induced periostitis was the most likely cause for the symptoms. Discontinuation of voriconazole led to complete resolution of pain within 48 hours.

Results
At one year post transplant, patient continued to be in remission and pain free.

Conclusion
Painful periostitis is a rare complication of long term voriconazole therapy which has only been recently reported in literature. Fluorosis and promotion of bone formation by osteoblast stimulation is the the proposed mechanism for voriconazole induced periostitis. Increased awareness of this rare condition can lead early correct diagnosis.

Session topic: 31. Infectious diseases, supportive care

Keyword(s): Side effects, Voriconazole

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies